GRI is developing GRI-0621 for chronic liver disease, alcoholic liver disease, and NASH. GRI-0621 is currently being evaluated in 60 patients in a Phase 2a clinical study, with data expected in 2017. The trial includes patients on a background of NASH, alcoholic steatohepatitis (ASH) and viral hepatitis.

A Phase 2b study in NASH patients with fibrosis is anticipated to start in 2017.